CPMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CPMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-15), Cannapharmarx's share price is $0.008. Cannapharmarx's Book Value per Share for the quarter that ended in Sep. 2024 was $-0.03. Hence, Cannapharmarx's PB Ratio of today is .
The historical rank and industry rank for Cannapharmarx's PB Ratio or its related term are showing as below:
During the past 3 years, the average Book Value Per Share Growth Rate was 44.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Cannapharmarx was 70.50% per year. The lowest was -81.10% per year. And the median was 24.30% per year.
The historical data trend for Cannapharmarx's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannapharmarx Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PB Ratio | Get a 7-Day Free Trial | 10.59 | - | - | - | - |
Cannapharmarx Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, Cannapharmarx's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Cannapharmarx's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cannapharmarx's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cannapharmarx's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Sep. 2024) |
= | 0.008 | / | -0.026 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cannapharmarx (OTCPK:CPMD) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Cannapharmarx's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Anthony Michael Panek | director | 95 SOUTH STATE STREET, SUITE 2300, SALT LAKE CITY UT 84111 |
Dominic Colvin | director, officer: Chief Executive Officer | C/O CANNAPHARMARX, INC., 2 PARK PLAZA, SUITE 1200-B, IRVINE CA 92614 |
John Hamilton Cassels | officer: Chief Financial Officer | SUITE 500, 209 8TH AVENUE SW, CALGARY A0 T2P 1B8 |
Richard Dale Orman | director | 302, 3204 RIDEAU PLACE SW, CALGARY A0 T2S1Z2 |
Andrew Clifford Steedman | officer: Chief Operating Officer | 1131 RIVERDALE AVE SW, CALGARY A0 T2S 0Y9 |
Marc R Branson | director | 977 KEITH ROAD, WEST VANCOUVER A1 V7T 1M6 |
Gary J Herick | 10 percent owner | 7609 RALSTON ROAD, ARVADA CO 80002 |
James F Samuelson | director | PO BOX 22, NEWPORT BEACH CA 92662 |
Matthew Nicosia | director, 10 percent owner | 2 PARK PLAZA, SUITE 400, IRVINE CA 92614 |
Robert M Liess | director | 2602 W. SAM ALLEN RD., PLANT CITY FL 33565 |
Mathew D Sherwood | director | P.O. BOX 4375, DILLON CO 80435 |
James E Smeeding | director | 4029 GILBERT AVENUE, DALLAS TX 75219 |
Elie M Khalife | director | 9447 E. CROSS CREEK STREET, WICHITA KS 67206 |
Steven J Rule | director | C/O CANNAPHARMARX, INC., ONE COLLINS DRIVE, SUITE 100, CARNEYS POINT NJ 08069 |
Alexander R Giaquinto | director | 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 08-24-2022
By ACCESSWIRE • 08-25-2023
By ACCESSWIRE • 03-05-2024
By ACCESSWIRE ACCESSWIRE • 02-08-2022
By ACCESSWIRE • 11-05-2024
By ACCESSWIRE ACCESSWIRE • 06-29-2022
By ACCESSWIRE • 03-12-2024
By ACCESSWIRE • 02-16-2024
By ACCESSWIRE ACCESSWIRE • 04-19-2023
By ACCESSWIRE ACCESSWIRE • 01-30-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.